Crossmark

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with mild cognitive impairment or early Alzheimer’s disease in the general population

Crossref DOI link: https://doi.org/10.1007/s10654-025-01220-1

Published Online: 2025-03-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Claus, Jacqueline J. https://orcid.org/0000-0001-7047-7064
vom Hofe, Ilse

van Ijlzinga Veenstra, Annekee

Licher, Silvan

Seelaar, Harro

de Jong, Frank J.

Neitzel, Julia

Vernooij, Meike W.

Ikram, M. Arfan

Wolters, Frank J.
Funding

Funding for this research was provided by:

ZonMw (Veni-09150162010108 and BIRD-NL-10510032120005, #10510032120003)

Hartstichting (CVON2018-28)

Alzheimer's Association (AARF-22-924982)
License Information

Text and Data Mining valid from 2025-03-23

Version of Record valid from 2025-03-23
More Information

Article History

Received: 14 March 2024

Accepted: 10 March 2025

First Online: 23 March 2025

Declarations

:

: The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Population Screening Act: Rotterdam Study.

: All participants provided written informed consent to participate in the study and to obtain information from their treating physicians.

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below